Saturday 17 October 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
62.11
0.72
−1.15%
Follow EXEL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 7 | 8 |
+8 more TTM periods Free account |
| 44.39% | 40.99% | 35.53% | 30.56% | ||
| 33.28% | 30.69% | 27.02% | 23.44% | ||
ROIC |
60.45% | 50.53% | 49.46% | 42.67% | |
Return on Tangible Assets |
87.68% | 89.31% | 68.85% | 59.82% | |
Average Days of Receivables |
48.28 | 50.54 | 45.14 | 49.41 | |
Free Cash Flow per Share |
4.62 | 3.50 | 3.11 | 2.77 | |
Free Cash Flow |
1,158.19 | 905.17 | 844.34 | 744.27 | |
Capital Expenditures |
(25.24) | (19.51) | (39.93) | (46.75) | |
| Other line items | |||||
Cash ROIC |
43.17% | 33.36% | 26.22% | 23.63% | |
Accounts Receivable Turnover |
7.93 | 7.78 | 8.40 | 7.90 | |
Accounts Payable Turnover |
2.64 | 2.52 | 2.47 | 1.82 | |
Inventory Turnover |
3.28 | 3.28 | 3.80 | 3.19 | |
Average Days of Payables |
166.43 | 104.36 | 129.19 | 119.87 | |
Days of Inventory on Hand |
122.41 | 114.95 | 94.57 | 129.59 | |
Tax Rate |
(0.17) | (0.17) | (0.17) | (0.22) | |
Research and Development Expense of Revenue |
33.84% | 34.21% | 35.56% | 37.62% | |
Selling, General and Administrative Expense of Revenue |
21.92% | 21.94% | 22.36% | 23.16% | |
Share Based Compensation of Revenue |
4.62% | 4.89% | 4.87% | 5.21% | |
Operating CF/Net income |
1.38 | 1.11 | 1.13 | 1.17 | |
Depreciation/Fixed assets |
0.31 | 0.30 | 0.29 | 0.28 | |
Capex/Depreciation |
(0.89) | (0.68) | (1.37) | (1.57) | |
Revenue per Share |
9.71 | 9.20 | 8.54 | 8.52 | |
Operating CF per Share |
4.72 | 3.58 | 3.26 | 2.95 | |
Capex per Share |
(0.10) | (0.08) | (0.15) | (0.17) | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 |
Columns are period end dates